{
  "id": 9742246,
  "title": "CVC, NSSK weigh $3.2bn Kobayashi Pharmaceutical take-private",
  "url": "https://urgent.news/2026/09/25/cvc-nssk-weigh-3-2bn-kobayashi-pharmaceutical-take-private",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-25T09:19:09.000Z",
  "source": {
    "name": "Private Equity Wire",
    "slug": "private-equity-wire",
    "url": "https://www.privateequitywire.co.uk/cvc-nssk-weigh-3-2bn-kobayashi-pharmaceutical-take-private/"
  },
  "original_language": "en",
  "account": "CVC Capital Partners and Nippon Sangyo Suishin Kiko (NSSK) are reportedly considering a joint bid of over JPY500bn ($3.2bn) to acquire Japanese pharmaceutical firm Kobayashi Pharmaceutical, according to Bloomberg. The potential takeover aims to privatize the company, which has faced scrutiny over supplements containing red yeast since early 2024. Kobayashi's shares have traded around 13% below their pre-controversy level, with the company's market capitalization currently at around ¥460bn. The takeover would offer a premium for shareholders, though the exact amount has not been disclosed. Oasis Management, a significant shareholder with a 14.4% stake, has been vocal in advocating for governance changes at Kobayashi. The founding family, through Akihiro Kobayashi, also holds an 11.9% stake in the company. The red yeast issue stems from complaints of illnesses linked to Kobayashi's nutritional supplements, leading to a recall of some products containing puberulic acid. Kobayashi has not definitively linked any deaths to its supplements but has faced criticism from Japanese health authorities. The company acknowledged a ¥12.7bn charge related to the recalls and compensation for health damage, affecting over 500 individuals.",
  "summary": "PE firm CVC Capital Partners and Japanese investment firm Nippon Sangyo Suishin Kiko (NSSK) are considering a bid of more than JPY500bn ($3.2bn) to take Japanese healthcare products company Kobayashi Pharmaceutical private, according to a report by Bloomberg citing unnamed people familiar with the matter.",
  "key_points": [
    "CVC Capital Partners and NSSK consider $3.2bn joint bid for Kobayashi Pharmaceutical.",
    "Takeover aims to privatize company amid red yeast supplement controversy.",
    "Oasis Management and Kobayashi family hold significant stakes in the firm."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}